Top Markets
Coin of the day
Polaryx Therapeutics, Inc. Common Stock Polaryx Therapeutics, Inc. Common Stock

Polaryx Therapeutics, Inc. Common Stock

PLYX
株式のランク #21586
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to... Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
株価
$2.10
最終同期: 2026-08-21
時価総額
$104.43M
変化(1日)
-2.10%
変化(1年)
-
US
取引 Polaryx Therapeutics, Inc. Common Stock (PLYX)

カテゴリー

Polaryx Therapeutics, Inc. Common Stock(PLYX)の収益
Aug 2026 時点の収益 TTM: 0
Polaryx Therapeutics, Inc. Common Stock の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Polaryx Therapeutics, Inc. Common Stock の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$12.62B -
US
$6.02B -
NL
$2.23B -
US
$15.74B -
AU
- -
CH